AARTI DRUGS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 501 INR | +0.14% |
|
+1.56% | +2.44% |
| Mar. 29 | Aarti Drugs Limited Announces Executive Cessation | CI |
| Jan. 31 | Aarti Drugs Begins Manufacturing Dermatology Products in Tarapur, India Facility | MT |
| Sales 2024 * | 26.12B 313M | Sales 2025 * | 29.48B 354M | Capitalization | 46B 552M |
|---|---|---|---|---|---|
| Net income 2024 * | 1.73B 20.76M | Net income 2025 * | 2.52B 30.19M | EV / Sales 2024 * | 1.76 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.56 x |
| P/E ratio 2024 * |
26.8
x | P/E ratio 2025 * |
18.4
x | Employees | 1,003 |
| Yield 2024 * |
0.94% | Yield 2025 * |
1.36% | Free-Float | 36.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Aarti Drugs Limited
| 1 day | +0.30% | ||
| 1 week | +1.72% | ||
| Current month | +15.66% | ||
| 1 month | +13.17% | ||
| 3 months | -6.16% | ||
| 6 months | +9.53% | ||
| Current year | +2.61% |
1 week
486.25
507.95
1 month
430.00519.80
Current year
430.00567.10
1 year
408.95645.00
3 years
310.80841.40
5 years
104.831 025.00
10 years
43.811 025.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 85-01-04 | |
Adhish P. Patil
DFI | Director of Finance/CFO | 41 | 12-07-05 |
Rushikesh Deole
CMP | Compliance Officer | - | 19-04-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 76 | 85-01-04 | |
| Director/Board Member | 61 | 87-01-01 | |
| Director/Board Member | 60 | 95-09-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +0.83% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 501 | +0.14% | 28 384 |
| 24-04-23 | 500.3 | +1.44% | 28,384 |
| 24-04-22 | 493.2 | -0.61% | 12,225 |
| 24-04-19 | 496.2 | +0.60% | 11,051 |
| 24-04-18 | 493.3 | -0.28% | 4,381 |
Delayed Quote Bombay S.E., April 24, 2024 at 05:43 am EDT
More quotes
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
Sector
Pharmaceuticals
Calendar
2024-05-15
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
500.3
INR
Average target price
562
INR
Spread / Average Target
+12.33%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.61% | 552M | |
| +27.92% | 672B | |
| +27.19% | 570B | |
| -4.59% | 360B | |
| +16.38% | 321B | |
| +9.39% | 300B | |
| +7.43% | 217B | |
| +5.90% | 199B | |
| -8.47% | 204B | |
| -8.58% | 149B |
- Stock Market
- Equities
- AARTIDRUGS Stock
